NASDAQ:LIFE aTyr Pharma - LIFE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.15 +0.18 (+9.14%) (As of 03/28/2023 02:39 PM ET) Add Compare Share Share Today's Range$1.95▼$2.2050-Day Range$1.88▼$2.4952-Week Range$1.82▼$5.97Volume658,613 shsAverage Volume268,140 shsMarket Capitalization$114.29 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media aTyr Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside790.5% Upside$19.25 Price TargetShort InterestHealthy0.45% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.25Based on 3 Articles This WeekInsider TradingSelling Shares$3,696 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.09) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.73 out of 5 starsMedical Sector70th out of 1,002 stocksBiological Products, Except Diagnostic Industry12th out of 166 stocks 3.5 Analyst's Opinion Consensus RatingaTyr Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.25, aTyr Pharma has a forecasted upside of 790.5% from its current price of $2.16.Amount of Analyst CoverageaTyr Pharma has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.45% of the outstanding shares of aTyr Pharma have been sold short.Short Interest Ratio / Days to CoveraTyr Pharma has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in aTyr Pharma has recently decreased by 6.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldaTyr Pharma does not currently pay a dividend.Dividend GrowthaTyr Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LIFE. Previous Next 4.0 News and Social Media Coverage News SentimentaTyr Pharma has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for aTyr Pharma this week, compared to 1 article on an average week.Search Interest34 people have searched for LIFE on MarketBeat in the last 30 days. This is an increase of 240% compared to the previous 30 days.MarketBeat Follows3 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, aTyr Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,696.00 in company stock.Percentage Held by InsidersOnly 4.36% of the stock of aTyr Pharma is held by insiders.Percentage Held by Institutions99.09% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for aTyr Pharma are expected to grow in the coming year, from ($1.09) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of aTyr Pharma is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of aTyr Pharma is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioaTyr Pharma has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About aTyr Pharma (NASDAQ:LIFE) StockaTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Read More Receive LIFE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LIFE Stock News HeadlinesMarch 28, 2023 | finance.yahoo.com2 “Strong Buy” Penny Stocks With Over 200% Upside on the HorizonMarch 21, 2023 | finance.yahoo.comaTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and ResolutionMarch 28, 2023 | Porter & Company (Ad)Biden’s Big Lie…Biden is about to steal the 2024 election... Not through voter suppression, collision with Big Tech, or anything else you might be thinking of. March 20, 2023 | finance.yahoo.comaTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational TherapiesMarch 10, 2023 | finanznachrichten.deaTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate UpdateMarch 9, 2023 | finance.yahoo.comaTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate UpdateMarch 9, 2023 | finance.yahoo.comAtyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue EstimatesMarch 8, 2023 | msn.comaTyr Pharma's Earnings: A PreviewMarch 28, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 4, 2023 | benzinga.comaTyr Pharma Stock (NASDAQ:LIFE), Analyst Ratings, Price Targets, PredictionsMarch 2, 2023 | finance.yahoo.comaTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial ResultsMarch 1, 2023 | finance.yahoo.comaTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND ApplicationFebruary 11, 2023 | benzinga.comaTyr Pharma Stock (NASDAQ:LIFE), Quotes and News SummaryFebruary 10, 2023 | finance.yahoo.comWith 37% stake, aTyr Pharma, Inc. (NASDAQ:LIFE) seems to have captured institutional investors' interestFebruary 9, 2023 | finance.yahoo.comaTyr Pharma Announces Pricing of Public Offering of Common StockFebruary 8, 2023 | finance.yahoo.comaTyr Pharma Announces Commencement of Public Offering of Common StockFebruary 6, 2023 | finance.yahoo.comaTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd.January 31, 2023 | finance.yahoo.comaTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International ConferenceJanuary 19, 2023 | finance.yahoo.comaTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or FibrosisJanuary 18, 2023 | marketwatch.comaTyr Pharma Gets Orphan Drug Designation for Efzofitimod in EuropeJanuary 18, 2023 | msn.comATyr Pharma therapy for lung disorder gets orphan drug status in EUJanuary 18, 2023 | finance.yahoo.comEuropean Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of SarcoidosisDecember 15, 2022 | finance.yahoo.comaTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase FragmentNovember 11, 2022 | finanznachrichten.deaTyr Pharma, Inc.: aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate UpdateNovember 10, 2022 | seekingalpha.comaTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call TranscriptNovember 10, 2022 | finance.yahoo.comAtyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue EstimatesNovember 10, 2022 | finance.yahoo.comaTyr Pharma to Present at Upcoming Investor ConferencesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LIFE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LIFE Company Calendar Last Earnings8/09/2021Today3/28/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:LIFE CUSIP53217V10 CIK1339970 Webwww.atyrpharma.com Phone(858) 731-8389Fax858-731-8394Employees49Year Founded2005Price Target and Rating Average Stock Price Forecast$19.25 High Stock Price Forecast$35.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+610.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,340,000.00 Net MarginsN/A Pretax Margin-436.58% Return on Equity-54.44% Return on Assets-46.19% Debt Debt-to-Equity Ratio0.01 Current Ratio5.83 Quick Ratio5.83 Sales & Book Value Annual Sales$10.39 million Price / Sales10.08 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.80Miscellaneous Outstanding Shares53,162,000Free Float50,844,000Market Cap$104.73 million OptionableOptionable Beta1.23 Social Links Key ExecutivesSanjay S. ShuklaPresident, Chief Executive Officer & DirectorJill M. BroadfootChief Financial OfficerLeslie NangleVice President-ResearchAndrew B. CubittVice President-External Scientific AlliancesPeter VilligerVice President-Corporate DevelopmentKey CompetitorsBrainstorm Cell TherapeuticsNASDAQ:BCLITCR2 TherapeuticsNASDAQ:TCRRTradeUP AcquisitionNASDAQ:UPTDCognition TherapeuticsNASDAQ:CGTXAptose BiosciencesNASDAQ:APTOView All CompetitorsInsiders & InstitutionsTang Capital Management LLCSold 990,023 shares on 2/15/2023Ownership: 0.425%Millennium Management LLCBought 68,106 shares on 2/15/2023Ownership: 0.235%Two Sigma Investments LPSold 17,476 shares on 2/14/2023Ownership: 0.560%Marshall Wace LLPSold 35,614 shares on 2/14/2023Ownership: 0.484%Susquehanna International Group LLPSold 98,400 shares on 2/14/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions LIFE Stock - Frequently Asked Questions Should I buy or sell aTyr Pharma stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIFE shares. View LIFE analyst ratings or view top-rated stocks. What is aTyr Pharma's stock price forecast for 2023? 5 equities research analysts have issued 12-month price objectives for aTyr Pharma's stock. Their LIFE share price forecasts range from $9.00 to $35.00. On average, they expect the company's stock price to reach $19.25 in the next twelve months. This suggests a possible upside of 877.2% from the stock's current price. View analysts price targets for LIFE or view top-rated stocks among Wall Street analysts. How have LIFE shares performed in 2023? aTyr Pharma's stock was trading at $2.19 at the beginning of the year. Since then, LIFE stock has decreased by 10.0% and is now trading at $1.97. View the best growth stocks for 2023 here. Are investors shorting aTyr Pharma? aTyr Pharma saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 240,900 shares, a decrease of 6.8% from the February 28th total of 258,500 shares. Based on an average trading volume of 249,600 shares, the short-interest ratio is presently 1.0 days. View aTyr Pharma's Short Interest. When is aTyr Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our LIFE earnings forecast. How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:LIFE) issued its earnings results on Monday, August, 9th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.13. When did aTyr Pharma's stock split? aTyr Pharma shares reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO? 3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). When did aTyr Pharma IPO? (LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers. What is aTyr Pharma's stock symbol? aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE." Who are aTyr Pharma's major shareholders? aTyr Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Alyeska Investment Group L.P. (4.75%), VR Adviser LLC (4.04%), Citigroup Inc. (1.50%), Dimensional Fund Advisors LP (0.69%), Renaissance Technologies LLC (0.57%) and Two Sigma Investments LP (0.56%). Insiders that own company stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla. View institutional ownership trends. How do I buy shares of aTyr Pharma? Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is aTyr Pharma's stock price today? One share of LIFE stock can currently be purchased for approximately $1.97. How much money does aTyr Pharma make? aTyr Pharma (NASDAQ:LIFE) has a market capitalization of $104.73 million and generates $10.39 million in revenue each year. The biotechnology company earns $-45,340,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. How can I contact aTyr Pharma? aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The official website for the company is www.atyrpharma.com. The biotechnology company can be reached via phone at (858) 731-8389, via email at investorrelations@atyrpharma.com, or via fax at 858-731-8394. This page (NASDAQ:LIFE) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.